Akero Therapeutics, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2019-06-19

Reporting Person: Young Jonathan (EVP, Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	192909	Direct
Common Stock	20000	Indirect
Common Stock	20000	Indirect
Common Stock	20000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.61	2028-07-29	Common Stock (65452)		Direct
Stock Option (Right to Buy)	$0.61	2028-10-17	Common Stock (121636)		Direct
Stock Option (Right to Buy)	$6.36	2029-01-15	Common Stock (72756)		Direct

Footnotes

F1: These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.

F3: Shares vested and became exercisable in equal monthly installments for a period of 48 months following October 1, 2018.

F4: Shares vested and became exercisable in equal monthly installments for a period of 48 months following January 1, 2019.